SecBot SecBot

SLXNW

Silexion Therapeutics Corp
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. E9· CIK 0002022416 Biotech & Drug Discovery
Warrants of Silexion Therapeutics Corp · SLXN stock page →
—
Market cap
$143.3K
Nano cap
1 year
−99.5%
from $34.70 · Oct 27
30 days
−32.9%
from $0.2480
52-week range
$0.1530–34.70
−100% from high · low Oct 16
Avg volume 20D
2.10M
Sep 30 spike 11.70M
Short interest
🔒 Subscribers only
Filing reports
5
analyzed by SecBot
SecBot read MIXED 5 reports · latest
Balance 1 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 5/5
Strongest BULLISH Silexion Therapeutics reported Q1 2026 financial results, highlighting a net loss of $2.7M (vs $1.7M in Q1…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • TrendDOWNTREND

    45% below its 50-day average.

Who's buying

13F
Top holderSharesValue
LINDEN ADVISORS LP337,500$9.5K
Clear Street Group Inc.218,165$6.6K
GOLDMAN SACHS GROUP INC125,103$3.8K
SUSQUEHANNA INTERNATIONAL GROUP, LLP92,073$2.8K
JANE STREET GROUP, LLC74,910$2.3K
PICTON MAHONEY ASSET MANAGEMENT57,175$1.7K
Neuberger Berman Group LLC31,552$959.00
GABELLI FUNDS LLC30,496$927.00

Quarterly 13F filings are due 45 days after each quarter ends.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 25, 2026 Listing status
Listing Status: SLXNW — Deficient (was Normal)
Silexion Therapeutics Corp - Warrant | Nasdaq Financial Status Indicator N → D
May 29, 2026 SEC
Silexion Therapeutics Corp effected a 1-for-10 reverse share split of its ordinary shares, effective May 28, 2026, to…
8-K — Impact 4/10
May 26, 2026 SEC
Silexion Therapeutics announced a 1-for-10 reverse share split, effective after market close on May 28, 2026, with…
8-K — Impact 5/10
May 18, 2026 SEC
Silexion Therapeutics reported Q1 2026 financial results, highlighting a net loss of $2.7M (vs $1.7M in Q1 2025) and…
8-K — Impact 7/10

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Aug 25, 2026
Listing
Listing Status: SLXNW — Deficient (was Normal)
Silexion Therapeutics Corp - Warrant | Nasdaq Financial Status Indicator N → D
Aug 11, 2026
Reg SHO list
Reg SHO Threshold: SLXNW exited the threshold list
SILEXION THERAPEUTICS CORP WT | On list since 2026-08-04
Aug 4, 2026
Reg SHO list
Reg SHO Threshold: SLXNW entered the threshold list
SILEXION THERAPEUTICS CORP WT | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding

SecBot reports

5 filings · 1 bullish · 1 bearish · 3 neutral
All SLXNW filing & press-release reports (5)